Socioeconomic status and survival after an invasive breast cancer diagnosis

BACKGROUND:

Women who live in geographic areas with high poverty rates and low levels of education experience poorer survival after a breast cancer diagnosis than women who live in communities with indicators of high socioeconomic status (SES). However, very few studies have examined individual‐level SES in relation to breast cancer survival or have assessed the contextual role of community‐level SES independent of individual‐level SES.

METHODS:

The authors of this report examined both individual‐level and community‐level SES in relation to breast cancer survival in a population‐based cohort of women ages 20 to 69 years who were diagnosed with breast cancer in Wisconsin between 1995 and 2003 (N = 5820).

RESULTS:

Compared with college graduates, women who had no education beyond high school were 1.39 times more likely (95% confidence interval [CI], 1.10‐1.76) to die from breast cancer. Women who had household incomes <2.5 times the poverty level were 1.46 times more likely (95% CI, 1.10‐1.92) to die from breast cancer than women who had household incomes ≥5 times the poverty level. Adjusting the analysis for use of screening mammography, disease stage at diagnosis, and lifestyle factors eliminated the disparity by income, but the disparity by education persisted (hazard ratio [HR], 1.27; 95% CI, 0.99‐1.61). In multilevel analyses, low community‐level education was associated with increased breast cancer mortality even after adjusting for individual‐level SES (HR, 1.57; 95% CI, 1.09‐2.27 for ≥20% vs <10% of adults without a high school degree).

CONCLUSIONS:

The current results indicated that screening and early detection explain some of the disparity according to SES, but further research will be needed to understand the additional ways in which individual‐level and community‐level education are associated with survival. Cancer 2011. © 2010 American Cancer Society.     

Prospective cohort study of lifetime physical activity and breast cancer survival

Few studies have examined the association between physical activity and disease outcomes in breast cancer survivors. Here, we report the association between lifetime total physical activity performed prior to diagnosis and disease outcomes in a population‐based sample of breast cancer survivors. A cohort of 1,231 women diagnosed with breast cancer between 1995 and 1997 was followed for a minimum of 8.3 years for any cancer progressions, recurrences and new primaries; and a minimum of 10.3 years for deaths. All treatment and follow‐up care received was abstracted from medical records. Data on physical activity including type (occupational, household, recreational) and dose (frequency, intensity and duration) performed during the entire lifetime until diagnosis were examined in Cox proportional hazards models as well as with cumulative incidence curves. An average of 126 MET‐hr/week were reported for total physical activity (of which 13.9, 46.9 and 65.3 MET‐hr/week were, respectively, for recreational, occupational and household activity). A decreased risk of breast cancer death and all deaths was observed among women in the highest versus the lowest quartiles of recreational activity (MET‐hr/week/year) (HR = 0.54, 95% CI = 0.36–0.79). Both moderate (0.56, 95% CI = 0.38–0.82) and vigorous intensity recreational activity (0.74, 95% CI = 0.56–0.98) decreased the risk of breast cancer death. Moderate intensity recreational activity decreased the risk of a recurrence, progression or new primary cancer (0.66, 95% CI = 0.48–0.91). No other association with breast cancer survival was observed for other types of physical activity. Prediagnosis recreational activity conferred a benefit for survival after breast cancer. Moderate intensity recreational activity was particularly protective. © 2008 Wiley‐Liss, Inc.     

Smoking and survival after breast cancer diagnosis in Japanese women: A prospective cohort study

The results of previous studies investigating whether there is an association between active smoking and risk of death among breast cancer patients have been inconsistent. We investigated the association between active and passive smoking and risk of all‐cause and breast cancer‐specific death among female breast cancer patients in relation to menopausal and tumor estrogen/progesterone receptor (ER/PR) status. The present study included 848 patients admitted to a single hospital in Japan from 1997 to 2007. Active or passive smoking status was assessed using a self‐administered questionnaire. The patients were followed until 31 December 2010. We used a Cox proportional‐hazard model to estimate hazard ratios (HR). During a median follow‐up period of 6.7 years, 170 all‐cause and 132 breast cancer‐specific deaths were observed. Among premenopausal patients, current smokers showed a non‐significant higher risk of all‐cause and breast cancer‐specific death. A duration of smoking >21.5 years was positively associated with all‐cause (HR = 3.09, 95% confidence interval [CI], 1.17–8.20) and breast cancer‐specific death (HR = 3.35, 95% CI: 1.22–9.23, P_trend = 0.035) among premenopausal patients. In premenopausal patients with ER+ or PR+ tumors, there was some suggestion that a longer duration of smoking was associated with higher risk of all‐cause and breast cancer‐specific death. Passive smoking demonstrated no significant risk. Our results suggest that a longer duration of active smoking is associated with an increased risk of all‐cause and breast cancer‐specific death among premenopausal patients, possibly with hormonal receptor‐positive tumors. Breast cancer patients should be informed about the importance of smoking cessation.     

Smoking at diagnosis and survival in cancer patients

The effect of smoking on survival in cancer patients is limited by the lack of structured prospective assessments of smoking at diagnosis. To assess the effect of smoking at diagnosis on survival, structured smoking assessments were obtained in a cohort of 5,185 cancer patients within 30 days of a cancer diagnosis between 1982 and 1998. Hazard ratios (HRs) or odds ratios were generated to analyze the effects of smoking at diagnosis on overall mortality (OM) and disease‐specific mortality (DSM) in a patient cohort from 13 disease sites containing at least 100 patients in each disease site. With a minimum of 12 years of follow‐up, current smoking increased OM risk versus recent quit (HR 1.17), former (HR 1.29) and never smokers (HR 1.38) in the overall cohort. Current smoking increased DSM risk versus former (HR 1.23) and never smokers (HR 1.18). In disease sites with proportionately large (>20%) recent quit cohorts (lung and head/neck), current smoking increased OM and DSM risks as compared with recent quit. Current smoking increased mortality risks in lung, head/neck, prostate and leukemia in men and breast, ovary, uterus and melanoma in women. Current smoking was not associated with any survival benefit in any disease site. Data using prospective structured smoking assessments demonstrate that current smoking increased long‐term OM and DSM. Standardized smoking assessment at diagnosis is an important variable for evaluating outcomes in cancer patients.     

三阴性乳腺癌临床病理特征、治疗方法及转移后生存情况分析

目的探讨三阴性乳腺癌的临床病理特征、治疗方法、转移情况与预后的关系。方法回顾性分析138例三阴性乳腺癌患者临床、病理及随访资料。结果三阴性乳腺癌患者3、5年无瘤生存率与绝经前、后发病,原发病灶大小,是否保乳,病理类型,化疗方案均无关（均P〉0．05）;与临床分期、淋巴结转移、病理分级均有相关性（均P〈0．05）。患者的3年无瘤生存率与家族史、与放疗均有相关性（均P〈0．05）。结论淋巴结转移、临床分期、病理分级均为影响预后的重要因素;保乳与否及常用的化疗方案与预后均无关;放疗可提高3年无瘤生存率,但不能提高5年无瘤生存率。术后转移者预后差,生存期〈2年。     

Active and passive smoking and breast cancer risk in middle-aged Japanese women

To examine the hypothesis that tobacco smoke is associated with the risk of female breast cancer, we estimated the relative risks of active and passive smoke in middle-aged Japanese women in a population-based prospective study. The cohort consisted of residents in 4 public health center areas, aged 40 to 59 years. A self-administered questionnaire survey was conducted in 1990. This analysis included 21,805 subjects, 180 of whom had developed breast cancer by December 31, 1999. When the reference was defined as never-active smokers without passive smoking, adjusted relative risks (RRs) were 1.9 (95% confidence interval [CI] = 1.0-3.6) in current active smokers, 1.2 (95% CI = 0.4-4.0) in ex-active smokers and 1.2 (95% CI = 0.8-1.6) in never-active smokers with passive smoking. The elevated risk for ever-smokers was clearly observed in premenopausal women at baseline (RR = 3.9, 95% CI = 1.5-9.9) but not in postmenopausal women (RR = 1.1, 95% CI = 0.5-2.5). In never-active smokers, the adjusted RR for passive smoking, residential or occupational/public tobacco smoke exposure was 1.1 (95% CI = 0.8-1.6). In premenopausal women, passive smoking increased the risk (RR = 2.6; 95% CI = 1.3-5.2) but not in postmenopausal women (RR = 0.7; 95% CI = 0.4-1.0). We conclude that tobacco smoking increases the risk of female breast cancer in premenopausal women.     

Smoking and breast cancer risk in Denmark

The effect of smoking on breast cancer risk was evaluated in a population-based case-control study, including 1,480 women diagnosed with breast cancer in Denmark between 1983–84. They were identified from the files of the nationwide clinical trial of the Danish Breast Cancer Cooperative Group and the Danish Cancer Registry. The control group was an age-stratified sample of 1,332 women from the general population. Data on risk factors were collected by self-administered questionnaires. The risk of breast cancer among current smokers and ex-smokers was similar to that in non-smokers, both risk estimates being close to unity. No dose-response relation was observed for any measure of smoking (age at start, duration, number of cigarettes per day, or cigarette-years of exposure) in all subjects, and when pre- and post-menopausal women were examined separately. These findings suggest that smoking is not associated with the risk of breast cancer.This work was undertaken during tenures of fellowships awarded to Dr. M. Ewertz by the Danish Cancer Society and the International Agency for Research on Cancer. The study was funded by the Danish Cancer Society, the Danish Medical Research Council, and Astrid Thaysens Legat.Dr Ewertz is with the Danish Cancer Registry, Institute of Cancer Epidemiology, Danish Cancer Society, Rosenvaengets Hovedvej 35, Box 839 DK-2100 Copenhagen Ø, Denmark.     

Active cigarette smoking and risk of breast cancer

Although epidemiological evidence on the role of active cigarette smoking in breast cancer risk has been inconsistent, recent literature supports a modest association between smoking and breast cancer. This association is particularly observed in women who smoke for a long duration, or who smoke for a long time prior to their first pregnancy. Here, we provide updated results on cigarette smoking and breast cancer risk in the Canadian National Breast Screening Study (NBSS). The NBSS is a large cohort of 89,835 women, aged 40–59, who were followed for a mean of 22.1 years, resulting in the ascertainment of 6,549 incident cases of breast cancer. Cox proportional hazard models were used to estimate hazard ratios (HR) and 95% confidence intervals (CI) for the association of cigarette smoking variables with breast cancer risk. We found breast cancer to be associated with duration (40 years vs. 0: HR = 1.57; 95%CI = 1.29–1.92), intensity (40 cigarettes per day vs. 0: HR = 1.21; 95%CI = 1.04–1.40), cumulative exposure (40 pack‐years vs. 0: HR = 1.19; 95%CI = 1.06–1.13) and latency (40 years since initiation vs. 0: HR = 1.19; 95%CI = 1.10–1.53) of cigarette smoking. Number of years smoked prior to first full‐term pregnancy was associated with higher risk of breast cancer than comparative years smoked post‐pregnancy (among parous women, 5 years pre pregnancy vs. 0: HR = 1.18; 95%CI = 1.10–1.26). These results strongly support a role for cigarette smoking in breast cancer etiology and emphasize the importance of timing of this exposure.     

Variation in survival after diagnosis of breast cancer in Switzerland.

BACKGROUND: Survival after diagnosis of cancer is a key criterion for cancer control. Major survival differences between time periods and countries have been reported by the EUROCARE studies. We investigated whether similar differences by period and region existed in Switzerland. METHODS: Survival of 11,376 cases of primary invasive female breast cancer diagnosed between 1988 and 1997 and registered in seven Swiss cancer registries covering a population of 3.5 million was analysed. RESULTS: Comparing the two periods 1988-1992 and 1993-1997, age-standardized 5 year relative survival improved globally from 77% to 81%. Furthermore, multivariate analysis adjusting for age, tumour size and nodal involvement identified regional survival differences. Survival was lowest in the rural parts of German-speaking eastern Switzerland and highest in urbanised regions of the Latin- and German-speaking northwestern parts of the country. CONCLUSIONS: This study confirms that survival differences are present even in a small and affluent, but culturally diverse, country like Switzerland, raising the issue of heterogeneity in access to care and quality of treatment.     

Family history and survival after colorectal cancer diagnosis

BACKGROUND

A history of colorectal cancer in a first‐degree relative is a recognized risk factor for developing this malignancy. The influence of a family history of colorectal cancer on survival after a diagnosis of colorectal cancer was examined in a large cohort of women.

METHODS

We analyzed data from 1001 women diagnosed with colorectal cancer while participating in a prospective cohort study. Data on family history were obtained before cancer diagnosis. We computed Cox proportional hazards for cancer‐specific and overall mortality according to a family history of colorectal cancer, adjusting for other predictors for survival.

RESULTS

Before diagnosis, 16% of colorectal patients reported a history of colorectal cancer in a first‐degree relative. Patients with a history of colorectal cancer in 1 or more first‐degree relatives experienced an adjusted hazard ratio (HR) for overall mortality of 1.32 (95% confidence interval [CI], 1.01–1.72) and colorectal cancer‐specific mortality of 1.38 (95% CI, 1.02–1.86) when compared with those without a family history. Moreover, patients with 2 or more affected relatives had an HR for overall mortality of 2.07 (95% CI, 1.14–3.76) and cancer‐specific mortality of 2.19 (95% CI, 1.10–4.38). The significant deleterious effect of family history was limited to patients with advanced disease at presentation and cancers originating in the colon.

CONCLUSIONS

Among women with colorectal cancer, a history of colorectal cancer in a first‐degree relative was associated with a significant decrease in survival. Additional study is needed to validate these findings and determine whether specific germline polymorphisms correlate with clinical outcomes. Cancer 2008. © 2008 American Cancer Society.     

Smoking and survival of colorectal cancer patients: Population‐based study from Germany

Current evidence on the association between smoking and colorectal cancer (CRC) prognosis after diagnosis is heterogeneous and few have investigated dose‐response effects or outcomes other than overall survival. Therefore, the association of smoking status and intensity with several prognostic outcomes was evaluated in a large population‐based cohort of CRC patients; 3,130 patients with incident CRC, diagnosed between 2003 and 2010, were interviewed on sociodemographic factors, smoking behavior, medication and comorbidities. Tumor characteristics were collected from medical records. Vital status, recurrence and cause of death were documented for a median follow‐up time of 4.9 years. Using Cox proportional hazards regression, associations between smoking characteristics and overall, CRC‐specific, non‐CRC related, recurrence‐free and disease‐free survival were evaluated. Among stage I–III patients, being a smoker at diagnosis and smoking ≥15 cigarettes/day were associated with lower recurrence‐free (adjusted hazard ratios (aHR): 1.29; 95% confidence interval (CI): 0.93–1.79 and aHR: 1.31; 95%‐CI: 0.92–1.87) and disease‐free survival (aHR: 1.26; 95%‐CI: 0.95–1.67 and aHR: 1.29; 95%‐CI: 0.94–1.77). Smoking was associated with decreased survival in stage I–III smokers with pack years ≥20 (Overall survival: aHR: 1.40; 95%‐CI: 1.01–1.95), in colon cancer cases (Overall survival: aHR: 1.51; 95%‐CI: 1.05–2.17) and men (Recurrence‐free survival: aHR: 1.51; 95%‐CI: 1.09–2.10; disease‐free survival: aHR: 1.49; 95%‐CI: 1.12–1.97), whereas no associations were seen among women, stage IV or rectal cancer patients. The observed patterns support the existence of adverse effects of smoking on CRC prognosis among nonmetastatic CRC patients. The potential to enhance prognosis of CRC patients by promotion of smoking cessation, embedded in tertiary prevention programs warrants careful evaluation in future investigations.     

Prospective cohort study of cigarette smoking and colorectal cancer risk in women

Epidemiological studies have consistently found a positive association between cigarette smoking and risk of colorectal adenomas, so the absence of a clear association between smoking and colorectal cancer risk may seem paradoxical. However, if colorectal cancer develops only after an induction period of about 35 years, as has been proposed recently, then studies in which all subjects have fewer than about 35 years between smoking commencement and assessment of outcome would be unlikely to detect this association. Few studies have examined smoking of several decades' duration among women. Therefore, in the cohort study reported here, we used proportional hazards models to estimate hazard ratios relating cigarette smoking to colorectal cancer risk among 89,835 women aged 40-59 years at recruitment into the Canadian National Breast Screening Study, a randomized controlled trial of mammography screening for breast cancer. During an average 10.6 years of follow-up (936,433 person-years), a total of 527 women were diagnosed with incident colorectal cancer (363 colon and 164 rectal). We found that smoking was associated with increased risk of rectal cancer 30 years or more after commencement, and especially with smoking of 40 years' duration or longer (hazard ratio=3.14, 95% CI=1.33-7.42). There was little evidence for altered risk of colon cancer. These results, along with those of other recent studies, support the hypothesis that tobacco smoking is an initiator, rather than a promoter, of rectal cancer. However, the results do not support an association with colon cancer risk, even with smoking of very long duration and high intensity.     

Effect of specialized diagnostic assessment units on the time to diagnosis in screen-detected breast cancer patients

Background:

The duration of the cancer diagnostic process has considerable influence on patients'' psychosocial well-being. Breast diagnostic assessment units (DAUs) in Ontario, Canada are designed to improve the quality and timeliness of care during a breast cancer diagnosis. We compared the diagnostic duration of patients diagnosed through a DAU vs usual care (UC).

Methods:

Retrospective population-based cohort study of 2499 screen-detected breast cancers (2011) using administrative health-care databases linked to the Ontario Cancer Registry. The diagnostic interval was measured from the initial screen to cancer diagnosis. Diagnostic assessment unit use was based on the biopsy and/or surgery hospital. We compared the length of the diagnostic interval between the DAU groups using multivariable quantile regression.

Results:

Diagnostic assessment units had a higher proportion of patients diagnosed within the 7-week target compared with UC (79.1% vs 70.2%, P<0.001). The median time to diagnosis at DAUs was 26 days, which was 9 days shorter compared with UC (95% CI: 6.4–11.6). This effect was reduced to 8.3 days after adjusting for all study covariates. Adjusted DAU differences were similar at the 75th and 90th percentiles of the diagnostic interval distribution.

Conclusions:

Diagnosis through an Ontario DAU was associated with a reduced time to diagnosis for screen-detected breast cancer patients, which likely reduces the anxiety and distress associated with waiting for a diagnosis.     

Coffee intake and breast cancer risk in the NIH-AARP diet and health study cohort

There are several biologic mechanisms whereby coffee might reduce breast cancer risk. Caffeine and caffeic acid, major coffee constituents, have been shown to suppress mammary tumor formation in animal models and to inhibit DNA methylation in human breast cancer cells, respectively. Coffee may also reduce risk through decreasing inflammation and influencing estrogen metabolism. However, epidemiologic studies have been inconsistent and few studies have examined the association by estrogen and progesterone receptor (ER/PR) status. We evaluated coffee intake for its effect on incident breast cancer in the National Institutes of Health-AARP Diet and Health Study cohort, which included 198,404 women aged 50-71 with no history of cancer, who in 1995-1996 completed a questionnaire capturing usual coffee intake over the past year. State cancer registry and mortality index linkage identified 9,915 primary incident breast carcinomas through December 2006; available information on hormone receptor (HR) status identified 2,051 ER+/PR+ and 453 ER-/PR- cancers. In multivariable proportional hazards models, coffee intake was not associated with breast cancer risk (p-value for trend = 0.38; relative risk = 0.98, 95% confidence interval: 0.91-1.07, for four or more cups per day as compared to women who never drank coffee), and results did not vary by body mass index or history of benign breast biopsy (p-value for interaction > 0.10). We found no evidence of a relationship with either caffeinated or decaffeinated coffee. Null findings persisted for risk of both HR-positive and -negative breast cancers. These findings from a large prospective cohort do not support a role of coffee intake in breast carcinogenesis.     

Mortality after breast cancer as a function of time since diagnosis by estrogen receptor status and age at diagnosis

Our aim was to estimate how long-term mortality following breast cancer diagnosis depends on age at diagnosis, tumor estrogen receptor (ER) status, and the time already survived. We used the population-based Australian Breast Cancer Family Study which followed-up 1,196 women enrolled during 1992–1999 when aged <60 years at diagnosis with a first primary invasive breast cancer, over-sampled for younger ages at diagnosis, for whom tumor pathology features and ER status were measured. There were 375 deaths (median follow-up = 15.7; range = 0.8–21.4, years). We estimated the mortality hazard as a function of time since diagnosis using a flexible parametric survival analysis with ER status a time-dependent covariate. For women with ER-negative tumors compared with those with ER-positive tumors, 5-year mortality was initially higher (p < 0.001), similar if they survived to 5 years (p = 0.4), and lower if they survived to 10 years (p = 0.02). The estimated mortality hazard for ER-negative disease peaked at ~3 years post-diagnosis, thereafter declined with time, and at 7 years post-diagnosis became lower than that for ER-positive disease. This pattern was more pronounced for women diagnosed at younger ages. Mortality was also associated with lymph node count (hazard ratio (HR) per 10 nodes = 2.52 [95% CI:2.11–3.01]) and tumor grade (HR per grade = 1.62 [95% CI:1.34–1.96]). The risk of death following a breast cancer diagnosis differs substantially and qualitatively with diagnosis age, ER status and time survived. For women who survive >7 years, those with ER-negative disease will on average live longer, and more so if younger at diagnosis.     

Does delay in diagnosis of breast cancer affect survival?

Summary 1675 breast cancer patients in the Auckland regional area have been divided into two major groups according to delay in diagnosis greater or less than six weeks. Overall there is no difference in survival although the variables tumour size, skin attachment, and nipple retraction are more common in the group with longer delay, and grade III tumours in those with short delay. Three important prognostic variables (the presence of tumour steroid receptors, positive axillary nodes, and distant metastases at diagnosis) are equally distributed and have a similar effect on survival within the two delay groups. However, in a subgroup of women with negative axillary nodes, short delay is associated with poorer survival, independent of tumour size. More tumours with grade III histology and a negative progesterone receptor status are found in this subgroup. Thus, short delay may constitute a new prognostic variable of some importance when in association with negative axillary nodes.     

Smoking history and survival among lung cancer patients

Two population-based case-control studies of lung cancer were conducred on the Island of Oahu, Hawaii, between 1979 and 1985. Interview information concerning smoking habits and other characteristics was obtained from a total of 463 men and 212 women with histologically confirmed lung cancer. Records from the Hawaii Tumor Registry were revicwed for information on the stage, histology, and follow-up status of these patients. Cigarette smoking was found to be positively related to the age-adjusted risk of death among women (relative risk (RR) -1.6; 95 percent confidence interval (CI)=1.0–2.4), but not among men (RR=0.8; 95 percent CI=0.5–1.2). Among women, the age-adjusted median survival time for never smokers was 33 months (n=53) compared with a median survival of 18 months (n=159) for smokers. Both past and current female smokers were at greater risk of death than never-smokers, and there was a significant trend in the risk of death by the number of cigarettes smoked per day (P=0.04), and the age at which the subjects started smoking (P=0.01). The effects of tumor stage and histology upon the association between tobacco smoking and survival were also explored.Drs Goodman, Kolonel, Wilkins, and Le Marchand are with the Epidemiology Program, Cancer Research Center of Hawaii, University of Hawaii, 1236 Laubela Street, Sulte 407, Honolulu, HI 96813. Dr Yoshizawa was at the Cancer Research Center at the time of the research and now is with Triton Biosciences Inc., Alameda, CA. Address reprint requests to Dr Goodman. This study was supported in part by Public Health Service grants PO1-CA-33619 and RO1-CA-26515, and contract NO1-CN-55424 from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services.